T Regulatory Cells IN LUPUS NEPHRITIS
- Conditions
- Lupus Nephritis
- Interventions
- Diagnostic Test: T-reg cells
- Registration Number
- NCT06428539
- Lead Sponsor
- Assiut University
- Brief Summary
* To study the role FoxP3-positive T regulatory cells in the pathogenesis of Lupus Nephritis, and determine the factors associated with levels of T regs .
* To compare the functional capacity of T regs in LN and in normal individuals.
- Detailed Description
Lupus Nephritis (LN) encompasses a group of glomerulonephrites, that occur in association with systemic lupus erythematosus (SLE). The mainstream theory that it is an immune disease resulting from loss of immune tolerance against body cells. The regulatory T cells (T regs ) are a subpopulation of immune cells that maintain tolerance to self-antigens and suppress autoimmune diseases. The main marker of Tregs is FoxP3 (forkhead box protein 3) positivity. Moreover, It has been suggested that functional capacity of Tregs is also compromised in autoimmune diseases. Studying the role of T regs in LN is a promising field that can help tailor current immune therapy and develop new treatment strategies.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 65
adults both genders clinical diagnosis of lupus nephritis
patients diagnosed with other renal pathologies, e.g. diabetic kidney disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description patients with active lupus nephritis T-reg cells patients with active lupus nephritis as active urinary sediment, or rising renal chemistry patients with lupus nephritis in remission T-reg cells Patients who were previously active, but now in remission normal individuals T-reg cells normal healthy participants
- Primary Outcome Measures
Name Time Method Association of FoxP3 and activity index baseline correlation between level of FoxP3 and activity index in the group with active LN.
Tregs in normal and lupus participants baseline mean difference of suppression capacity of Tregs between normal participants and patients with active LN.
FoxP3 between groups baseline mean difference of FoxP3 between groups.
- Secondary Outcome Measures
Name Time Method